Sage Journals: Discover world-class research

Abstract

Objective

MicroRNA-related single-nucleotide polymorphisms (miR-SNPs) can alter microRNA (miRNA) expression profiles, thereby influencing the risk of rheumatic diseases. Herrin a case control study, six miR-SNPs in miRNA processing machinery genes, namely RAN (rs14035), XPO5 (rs11077), Dicer (rs3742330), GEMIN3 (rs197412), GEMIN4 (rs2740348), and TNRC6B (rs9623117), were genotyped to assess their correlation with the risk of systemic lupus erythematosus (SLE).

Methods

We included 119 patients with SLE and 130 healthy controls. The genotypes of the six miR-SNPs were determined using polymerase chain reaction (PCR). Serum cytokine levels were assessed using a cytometric bead array, and fluorescent probe technology was used to determine plasma reactive oxygen species (ROS) levels.

Results

The AA genotype of Dicer was correlated with a 0.566-fold decreased risk of SLE compared with that of the AG + GG genotype (odds ratio, 0.566; 95% CI, 0.342–0.935; p = .026), and the rs3742330 A allele was associated with a significantly decreased risk of SLE (p = .035) compared with that of the rs3742330G allele. Additionally, AA genotype carriers exhibited lower levels of interleukin-6 (IL-6) in the blood (p = .013). Subsequent analysis revealed increased ROS production in patients with SLE than that in the controls (621.042 ± 425.285 vs 499.966 ± 302.273, p = .011).

Conclusion

Our findings suggest that ROS generation participates in SLE pathogenesis. The identification of Dicer gene SNP rs3742330 as a potential modifier of SLE risk via mediating IL-6 overproduction suggests a potential avenue for targeted interventions to manage SLE and its associated immune dysregulation.

Keywords

systemic lupus erythematosus microRNA-related single-nucleotide polymorphism cytokine reactive oxygen species

Introduction

Systemic lupus erythematosus (SLE) is a complex and chronic autoimmune disorder characterized by the production of autoantibodies targeting cytoplasmic and nuclear antigens, leading to diverse immunological and clinical manifestations.^1,2 In China, the prevalence of SLE ranges from 40 to 70 per 1000 people, with a ratio of 1:9 for males and females respectively.³ Several factors, including environmental influences, cytokines, genetic variations, and oxidative stress, contribute to the onset and progression of SLE; however, the precise etiology remains unclear.^4–6

MicroRNAs (miRNAs), non-coding ssRNA molecules of 19–22 nucleotides, participate in crucial biological processes, including metabolism, proliferation, apoptosis, differentiation, stress responses, and hormonal secretion.^7–9 Growing evidence suggests the involvement of miRNAs in rheumatic disorders, including rheumatoid arthritis (RA), SLE, and Sjögren’s syndrome.^10–12 During the processing of miRNA to produce a 21-base-pair dsRNA, processing of the long primary miRNA transcripts takes place in the nucleus via RNase III Drosha generating pre-miRNA (precursor miRNA), and then with both RAN-GTPase (RAN) and exportin-5 (XPO5), the pre-miRNA becomes located in the cytoplasm, where the processing of the pre-miRNA takes place by RNase III Dicer and the transactivation-responsive RNA-binding protein. This results in the formation of miRNA duplex that decompresses releasing mature mi-RNA. The RNA-induced silencing complex, containing GEMIN3/4, directs mature miRNA to its target messenger RNA sites.^13–18 miRNA can inhibit the expression of proteins by either degradation of mRNA or inhibition of translation. Single-nucleotide polymorphisms in miRNA-related genes (miR-SNPs), including miRNA processing machinery and binding sites, can modify miRNA expression and influence the risk of rheumatic diseases, such as rheumatoid arthritis, osteoarthritic chondrocytes, and polymyositis.^18–20

Cytokines and oxidative stress play significant roles in SLE pathogenesis. An imbalance between anti- and pro-inflammatory cytokines contributes to SLE inflammation and tissue damage.²¹ Additionally, reactive oxygen species (ROS)-modified DNA generates new antigen epitopes, forming immunological complexes with circulating anti-DNA antibodies and initiating SLE pathogenesis.²²

In this case-control study, genotyping of six miR-SNPs in miRNA processing machinery genes—RAN (rs14035), XPO5 (rs11077), Dicer (rs3742330), GEMIN3 (rs197412), GEMIN4 (rs2740348), and TNRC6B (rs9623117)—was performed to assess their correlation with SLE risk. Cytokine and ROS roles in SLE were also investigated.

Methods

Study population

In accordance with the 1997 classification criteria of the American College of Rheumatology, 119 women with SLE treated between May 2017 and October 2023 at the Second Hospital of Hebei Medical University were recruited as the cases group. Additionally, 130 age-matched healthy women, devoid of any autoimmune disease history, were included in this study. The clinical characteristics of the 119 patients, including 67 cases with rashes, 9 with ulcers, 40 with arthritis, 12 with serositis, 57 with anti-dsDNA positivity, 39 with lupus nephritis (LN), 22 with neuropsychiatric SLE (NPSLE), and 65 with hematological abnormalities, were retrospectively collected (Table 2). The clinical disease activity of SLE was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). All individuals provided written informed consent, and the study was conducted in adherence to the Declaration of Helsinki under the supervision and approval of the Human Tissue Research Committee of the Second Hospital of Hebei Medical University (2022-R730).

Genotyping of miR-SNPs

Genomic DNAs were extracted using the TIANGEN Blood Genomic Extraction Kit (TIANGEN, Beijing, China). The ligation detection reaction was employed for genotyping the six miR-SNPs of miRNA processing genes. This involved amplifying the gene fragments flanking miR-SNP sites using sequences obtained from the National Center for Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/snp/). The ligated products with different lengths were separated using the ABI PRISM 3730XL DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) was performed using the PCR Master Mix kit (2×) (Yisheng, Shanghai, China) as per the manufacturer’s instructions. The PCR primer and probe sequences are presented in Table 1.

Table 1.

Primers and probes.

Gene	SNP	Primer sequence	Probe sequence
RAN	rs14035	AGGGTAATATTTTCTTTTATGGC	ctgaAGTAATCATGTTTTAATGTAGAACC
		TTTAACAGCAAGAATTCCCAA	ctgactgAGTAATCATGTTTTAATGTAGAACT
		TTTAACAGCAAGAATTCCCAA	TCAAACAGGATGGAACATCAGTGGActg
XPO5	rs11077	AAGGGCAAGATGTGTGAAC	AAGGGGATGTTAGCACTAAAGACTG
		ATGGTACAGGCTACTGCTAA	ctgAAGGGGATGTTAGCACTAAAGACTT
		ATGGTACAGGCTACTGCTAA	CCCAGCCCTGGTCCTTGGAGGTACT
Dicer	rs3742330	GCAAATGGGTTAAAGACTCTTAA	ctgactgaTTCAATCTTGTGTAAAGGGATTAGA
		TGCAGAGGATCACTGGAATC	ctgactgactgTTCAATCTTGTGTAAAGGGATTAGG
		TGCAGAGGATCACTGGAATC	CACCCTAACAGAGCAAGATCCAATActgact
GEMIN3	rs197412	TGGAAATCATCAGGCACTAC	ATGGTTTTGTGAGAAATAAAGTTAC
		GCTGTAAGAATCACTGTCACT	ctgATGGTTTTGTGAGAAATAAAGTTAT
		GCTGTAAGAATCACTGTCACT	TGAACAGAGAGTCCCTGTGTTGGCA
GEMIN4	rs2740348	TCTATCACTGTTTCCAGCAG	ctgaGCAGCCTCAACACCAAGTCTGGCTC
		TTTGCCTCTGAGAAGAAGTG	ctgactgGCAGCCTCAACACCAAGTCTGGCTG
		TTTGCCTCTGAGAAGAAGTG	TCGGAAGAGGGCCCTGTTACTCCCCctg
TNRC6B	rs9623117	TTCTGTCTCCTCCTATCCATT	ctgactgactgaTCTCCCTGTTACTCTTAAGTAGTGC
		GCAACTGAAAGCAACTTAGC	ctgactgactgactgTCTCCCTGTTACTCTTAAGTAGTGT
		GCAACTGAAAGCAACTTAGC	CTCCTTTCCCCATCCACCCCATCTCctgactgac

Measurement of cytokine levels

A filter plate V02 (BioLegend, San Diego, CA) equipped with a human TH1/2 panel (8-Plex) was used for measuring the levels of cytokines, such as interleukin (IL)-2/4/5/6/10/13, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α. The procedure was conducted in darkness at room temperature, involving the addition of 25 μL of the serum sample (two-fold dilution using an assay buffer) to an equivalent volume of antibodies for each cytokine. Subsequently, the mixture was incubated, combined with beads, and shaken for 1 h at approximately 800 r/min, followed by the addition of streptavidin–phycoerythrin (SA-PE) into the tubes, with a subsequent 30-min shaking period at approximately 800 r/min. The quantification of the phycoerythrin fluorescence signal in the analyte-specific bead region and the determination of specific analyte concentrations were performed using the MACSQuant Analyzer 10 flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and data analysis software from BioLegend (San Diego, CA), respectively.

ROS measurement

ROS levels were monitored using the BBOXiProbe® Plasma Active Oxygen Detection Kit (BestBio Technology, Shanghai, China). Plasma (100 μL) was incubated with 10 μL of O12 probes at 37°C in darkness for 30 min, and fluorescence absorbance was measured at 488 nm (excitation) and 520 nm (emission) using a fluorescence plate reader (BIOTEK, Winooski, VT, USA).

Statistical analysis

Statistical analyses were conducted using SPSS software (version 21.0; SPSS Inc., Chicago, IL, USA). For continuous variables, we employed either the Student’s t-test or rank sum test, whereas the chi-square test or Fisher’s exact test was used to evaluate qualitative variables. We used either Spearman’s or Spearman’s rank correlation analysis to assess the correlation between variables. A sample size of 117 yielded 90% power to detect a medium effect size (W) of 0.30, using a one-degree-of-freedom chi-square test with a significance level (alpha) of 0.05 for PASS 15. A p-value (two-sided) < .05 indicated a significant difference.

Results

Genotyping and patient characteristics

In the present study, 119 patients with SLE and 130 healthy controls were enrolled, and the genotyping of six miR-SNPs in miRNA processing machinery genes is detailed in Table 2. No significant differences in age or sex were observed between the two groups.

Table 2.

Clinical data of SLE patients and controls.

Group	SLE patients (n = 119)	Controls (n = 130)	T value	p
Age (year)	40.218 ± 15.537	42.185 ± 9.735	−1.184	0.238
Manifestations
Rash	67 (56.3%)	—
Arthritis	40 (33.6%)	—
Serositis	12 (10.1%)	—
Ulcer	9 (7.5%)	—
Lupus nephritis	39 (32.8%)	—
Neuropsychiatric SLE	22 (18.5%)	—
Anti-dsDNA (+)	57 (47.9%)	—
Hematological abnormalities	65 (54.6%)	—
Disease duration (years)		—
≤1	71 (59.7%)	—
1–5	25 (21.0)	—
≥6	23 (19.3%)	—

SLE: systemic lupus erythematosus; Anti-dsDNA: anti-double stranded deoxyribonucleic acid; SLEDAI: systemic lupus erythematosus disease activity index; χ²: chi-square.

Genetic models and Dicer gene-located SNP analysis

Three genetic models (co-dominant, dominant, and recessive) were employed to investigate the potential association between the six miR-SNPs and SLE risk. The genotype distribution frequencies of SNPs (rs14035, rs11077, rs197412, rs2740348, and rs9623117) did not exhibit statistically significant differences (Table 3).

Table 3.

Associations of the six SNPs with systemic lupus erythematosus risk.

Gene SNP		Genotype	Genotype number		p	OR	95% CI
Gene SNP		Genotype	SLE	Controls	p	OR	95% CI
RAN (rs14035) (C/T)	Codominant	CC	74 (62.2%)	95 (73.1%)	.499	0.467	0.108–2.019
		CT	40 (33.6%)	32 (24.6%)	1.000	0.750	0.167–3.378
		TT	5 (4.2%)	3 (2.3)		1
	Dominant	CC	74 (62.2%)	95 (73.1%)	.066	0.606	0.354–1.036
		CT + TT	45 (37.8%)	35 (26.9%)		1
	Recessive	CC + CT	114 (95.8%)	127 (97.7%)	.626	0.539	0.126–2.304
		TT	5 (4.2%)	3 (2.3%)		1
	Allele	C	188 (79.0%)	222 (85.4%)	.062	0.644	0.405–1.024
		T	50 (21.0%)	38 (14.6%)		1
XPO5 (rs11077) (T/G)	Codominant	TT	102 (85.7%)	110 (84.6%)	1.000	0.927	0.057–15.020
		TG	16 (13.5%)	19 (14.6%)	1.000	0.842	0.049–14.565
		GG	1 (0.8%)	1 (0.8%)		1
	Dominant	TT	102 (85.7%)	110 (84.6%)	.808	1.091	0.541–2.198
		TG + GG	17 (14.3%)	20 (15.4%)		1
	Recessive	TT + TG	118 (99.2%)	129 (99.2%)	1.000	0.915	0.057–14.789
		GG	1 (0.8%)	1 (0.8%)		1
	Allele	T	220 (92.4%)	239 (91.9%)	.831	1.074	0.557–2.069
		G	18 (7.6%)	21 (8.1%)		1
Dicer (rs3742330) (A/G)	Codominant	AA	50 (42.0%)	73 (56.2%)	.158	0.527	0.214–1.295
		AG	56 (47.1%)	47 (36.2%)	.851	0.917	0.369–2.279
		GG	13 (10.9%)	10 (7.6%)		1
	Dominant	AA	50 (42.0%)	73 (56.2%)	.026	0.566	0.342–0.935
		AG + GG	69 (58.0%)	57 (43.8%)		1
	Recessive	AA + AG	106 (89.1%)	120 (92.4%)	.379	0.679	0.286–1.613
		GG	13 (10.9%)	10 (7.6%)		1
	Allele	A	156 (65.5%)	193 (74.2%)	.035	0.660	0.449–0.971
		G	82 (34.5%)	67 (25.8%)		1
GEMIN3 (rs197412) (T/C)	Codominant	TT	52 (43.7%)	56 (43.1%)	.728	0.857	0.359–2.047
		CT	54 (45.4%)	62 (47.7%)	.621	0.804	0.338–1.910
		CC	13 (10.9%)	12 (9.2%)		1
	Dominant	TT	52 (43.7%)	56 (43.1%)	.921	1.026	0.621–1.694
		CT + CC	67 (56.3%)	74 (56.9)		1
	Recessive	TT + CT	106 (89.1%)	118 (90.8%)	.657	0.829	0.363–1.896
		CC	13 (10.9%)	12 (9.2%)		1
	Allele	T	158 (66.4%)	174 (66.9%)	.899	0.976	0.672–1.417
		C	80 (33.6%)	86 (33.1%)		1
GEMIN4(rs2740348) (G/C)	Codominant	GG	2 (1.7%)	2 (1.5%)	1.000	1.040	0.144–7.530
		GC	18 (15.1%)	25 (19.2%)	.394	0.749	0.385–1.458
		CC	99 (83.2%)	103 (79.3%)		1
	Dominant	GG	2 (1.7%)	2 (1.5%)	1.000	1.094	0.152–7.892
		GC + CC	117 (98.3%)	128 (98.5%)		1
	Recessive	GG + GC	20 (16.8%)	27 (20.8%)	.425	0.771	0.406–1.463
		CC	99 (83.2%)	103 (79.2%)		1
	Allele	G	22 (9.2%)	29 (22.3%)	.482	0.811	0.452–1.455
		C	216 (90.8%)	231 (77.7%)		1
TNRC6B(rs9623117) (C/T)	Codominant	CT	10 (8.4%)	12 (9.2%)	.818	0.902	0.375–2.172
		TT	109 (91.6%)	118 (90.8%)		1
	Allele	C	10 (4.2%)	12 (4.6%)	.822	0.906	0.384–2.138
		T	228 (95.8%)	248 (95.4)		1

SLE: systemic lupus erythematosus; χ²: chi-square; OR: odds ratio; CI: confidence interval.

In the dominant model, the Dicer gene-located SNP rs3742330 revealed that the genotype frequencies for AA and AG + GG were 42.0% and 58.0% in patients with SLE, whereas in controls, they were 56.2% and 43.8%, respectively. The AA genotype was correlated with a 0.566-fold decreased risk of SLE compared with that of the AG + GG genotype (odds ratio, 0.566; 95% CI, 0.342-0.935; p = .026, Table 3). Additionally, the analysis revealed that the rs3742330 A allele was associated with a significantly decreased risk of SLE (p = .035) compared with that of the rs3742330 G allele.

Cytokine levels, clinical parameters, and their association with ROS levels

Assessment of the IL-2/4/5/6/10/13, IFN-γ, and TNF-α cytokine levels served for the purpose of evaluating their association with this SLE risk-correlated miR-SNPs by Wilcoxon rank sum test (Figure 1). The AA rs3742330 genotype displayed lower IL-6 expression than that of the AG + GG genotype (p = .013), suggesting that the Dicer SNP may participate in SLE pathogenesis by alteration of IL6 expression.

Figure 1.

The association of rs3742330 genotype with cytokines.

Comparison of different clinical parameters, including SLEDAI-2K, lupus nephritis, and neuropsychiatric SLE, with cytokine levels is depicted in Figures 2–4. However, no significant differences were observed between groups. An assessment of different clinical classifications, including lupus nephritis, neuropsychiatric SLE, and hematological abnormalities, in relation to SLE risk-associated miR-SNPs is presented in Table S1. However, no significant differences were observed between groups.

Figure 2.

The association of SLEDAI-2K with cytokines.

Figure 3.

The association of lupus nephritis with cytokines.

Figure 4.

The association of neuropsychiatric SLE with cytokines.

A subsequent investigation into SLE risk-associated miR-SNPs and ROS levels revealed no significant difference (AA: 615.080 ± 408.763 vs AG + GG: 625.362 ± 439.787, p = .896). Additional analysis revealed that in comparison to the control, ROS levels in the SLE group exhibited higher expression than control group and this was statistically significant (621.042 ± 425.285 versus 499.966 ± 302.273, p = .011, Figure 5). Spearman’s correlation analysis indicated no association between IL-6 and ROS levels.

Figure 5.

ROS level in SLE patients. (A) The ROS levels in AA and AG + GG genotypes of rs3742330. (B) The ROS levels in SLE patients and controls.

Discussion

In this study, we genotyped six miR-SNPs in miRNA processing machinery genes—RAN (rs14035), XPO5 (rs11077), Dicer (rs3742330), GEMIN3 (rs197412), GEMIN4 (rs2740348), and TNRC6B (rs9623117)—to explore their correlation with SLE risk. Our findings revealed an association between the Dicer gene-located SNP rs3742330 and SLE risk, with the rs3742330 A allele significantly linked to a decreased risk of SLE compared with that of the rs3742330 G allele.

Dicer, a member of the RNase III family, plays a crucial role in cleaving dsRNAs to generate small interfering RNAs and miRNAs, thus suppressing the target gene expression.^23,24 Dicer-controlled miRNA pathways are involved in the function and immune tolerance of Treg cells.^25–27 Altered Dicer expression in Tregs from lupus-prone MRL-Fas^lpr/lpr mice exhibited a diminished suppressive capacity and an altered phenotype characterized by expressional changes of CD62L and CD69. The altered miRNA profiles mediated by reduced Dicer expression may be implicated in the functional alterations in the Tregs, potentially initiating the SLE development.²⁸ The miRNA profile changes influenced by the Dicer gene 3′-untranslated region (UTR)-located miR-SNP rs3742330 could modulate the SLE process by influencing miRNA expression profiles; however, the precise target miRNAs involved in this process remain to be identified.

Our observation of an association between the Dicer AA genotype and decreased IL-6 levels aligns with previous research suggesting that reduced Dicer expression promotes IL-6 expression in inflamed colon tissues.²⁹ IL-6, a multifunctional pro-inflammatory cytokine, modulates the inflammatory response, influences B cell differentiation into plasma cells that secret immunoglobulin,³⁰ and contributes to autoantibody production. Moreover, IL-6-knockout mice exhibit delayed lupus nephritis onset and prolong survival.^31,32 Concordantly, IL-6 expression is also significantly increased in patients with SLE in addition to correlating with disease activity.³³ This implies that Dicer may regulate IL-6 expression by modulating miRNA expression, thereby influencing the progression of SLE.

Consistent with prior studies, our data indicated higher ROS levels in patients with SLE compared with those in healthy controls. Aberrant ROS levels can induce oxidative damage to intracellular components, including lipids, DNA, proteins, and phospholipids, potentially triggering cellular dysfunction or autoimmune responses.³⁴ Additionally, ROS can initiate the formation of pro-inflammatory cytokines through the activation of the nuclear factor-κB axis and contribute to the generation of SLE autoantigens, including the apoptotic bleb and neutrophil extracellular trap.³⁵

However, our study has certain limitations, including its single-center nature and a relatively small sample size. Further investigations involving data from multiple centers and a larger participant pool are warranted. Additionally, the exact mechanism by which the identified SNP contributes to the risk of developing SLE remains unknown and requires further investigation.

Conclusion

Our findings suggest that the SNP rs3742330 located in Dicer may modify SLE risk by mediating IL-6 overproduction. ROS generation also participates in SLE pathogenesis.

Supplemental Material

Supplemental Material - Single nucleotide polymorphisms in the Dicer gene modify the risk of systemic lupus erythematosus

Supplemental Material for Single nucleotide polymorphisms in the Dicer gene modify the risk of systemic lupus erythematosus by Jingjing Zhang, Yufei Zhao, Song Wang, Shasha Zhang, Xiaoyun Zhang, Chenxing Peng and Qingyi Liu in European Journal of Inflammation.

Footnotes

Acknowledgements

We would like to thank all patients for their participation.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research,authorship,and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research,authorship,and/or publication of this article: This work was supported by the Key Science and Technology Research Program from Health Commission of Hebei Province (grant number 20230133).

Ethical statement

ORCID iDs

Jingjing Zhang

Qingyi Liu

Supplemental Material

Supplemental material for this article is available online.

References

Fortuna

Brennan

. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin 2013; 57(4): 631–655.

Oku

Atsumi

. Systemic lupus erythematosus: nothing stale her infinite variety. Mod Rheumatol 2018; 28(5): 758–765.

Zhang

Leng

, et al. Chinese SLE treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 2013; 22(11): 1192–1199.

Carter

Barr

Clarke

. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016; 12(10): 605–620.

Hsu

Chiu

Wang

, et al. Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice. J Cell Mol Med 2013; 17(10): 1308–1315.

Pan

Gong

Xiao

, et al. Basophil activation-dependent autoantibody and interleukin-17 production exacerbate systemic lupus erythematosus. Front Immunol 2017; 8: 348.

Loh

Norman

Lai

, et al. The regulatory role of MicroRNAs in breast cancer. Int J Mol Sci 2019; 20(19): 4940.

Malumbres

. miRNAs and cancer: an epigenetics view. Mol Aspect Med 2013; 34(4): 863–874.

Wen

Martin

. How do microRNAs regulate gene expression? Biochem Soc Trans 2008; 36: 6.

10.

Evangelatos

Fragoulis

Koulouri

, et al. MicroRNAs in rheumatoid arthritis: from pathogenesis to clinical impact. Autoimmun Rev 2019; 18(11): 102391.

11.

Schell

Rahman

ZSM

. miRNA-mediated control of B cell responses in immunity and SLE. Front Immunol 2021; 12: 683710.

12.

Reale

D’Angelo

Costantini

, et al. MicroRNA in sjögren’s syndrome: their potential roles in pathogenesis and diagnosis. J Immunol Res 2018; 2018: 7510174.

13.

Cullen

. Transcription and processing of human microRNA precursors. Mol Cell 2004; 16(6): 861–865.

14.

Lee

Ahn

Han

, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425(6956): 415–419.

15.

Qin

Macara

, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17(24): 3011–3016.

16.

Chendrimada

Gregory

Kumaraswamy

, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436(7051): 740–744.

17.

Ryan

Robles

Harris

. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10(6): 389–402.

18.

Zhao

, et al. Single-nucleotide polymorphisms of microRNA processing machinery genes and risk of colorectal cancer. OncoTargets Ther 2015; 8: 421–425.

19.

Esmaeilzadeh

Saghi

Hassani

, et al. Strong association of common variants in the miRNA-binding site of NOD2 gene with clinicopathological characteristics and disease activity of systemic lupus erythematosus. Clin Rheumatol 2021; 40(11): 4559–4567.

20.

Papathanasiou

Mourmoura

Balis

, et al. Impact of miR-SNP rs2910164 on miR-146a expression in osteoarthritic chondrocytes. Adv Med Sci 2020; 65(1): 78–85.

21.

Idborg

Oke

. Cytokines as biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. Int J Mol Sci 2021; 22(21): 11327.

22.

Khan

Alam

Moinuddin , et al. Oxygen free radical modified DNA: implications in the etiopathogenesis of Systemic lupus erythematosus. Indian J Clin Biochem 2009; 24(2): 123–130.

23.

Bernstein

Caudy

Hammond

, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409(6818): 363–366.

24.

McManus

Sharp

. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3(10): 737–747.

25.

Cobb

Hertweck

Smith

, et al. A role for Dicer in immune regulation. J Exp Med 2006; 203(11): 2519–2527.

26.

Zhou

Jeker

Fife

, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008; 205(9): 1983–1991.

27.

Kohlhaas

Garden

Scudamore

, et al. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009; 182(5): 2578–2582.

28.

Divekar

Dubey

Gangalum

, et al. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol 2011; 186(2): 924–930.

29.

Chen

Liu

, et al. Rescuing Dicer expression in inflamed colon tissues alleviates colitis and prevents colitis-associated tumorigenesis. Theranostics 2020; 10(13): 5749–5762.

30.

Yang

Liang

Qin

, et al. A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk. Rheumatol Int 2014; 34(2): 199–205.

31.

Clark

Markham

Sloan

, et al. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin Immunol 2013; 148(3): 335–343.

32.

Cash

Relle

Menke

, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 2010; 37(1): 60–70.

33.

Mellor-Pita

Citores

Castejon

, et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009; 76(4): 261–270.

34.

Kowaltowski

Vercesi

. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26(3-4): 463–471.

35.

Lee

Lin

, et al. The pathogenesis of systemic lupus erythematosus - from the viewpoint of oxidative stress and mitochondrial dysfunction. Mitochondrion 2016; 30: 1–7.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.16 MB

0.00 MB